Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Extension Study of Niraparib in Ovarian and Breast Cancer
NCT04641247Phase 2Recruiting
- Sponsor
- GSK
- Start
- Apr 2021
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 2 trial of niraparib in ovarian cancer, breast cancer, sponsored by GSK. Started Apr 2021; status: recruiting.
02
Drugs
niraparib
03
Conditions
ovarian cancerbreast cancer
Beyond the preview
Go deeper on NCT04641247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04641247.